ADx NeuroSciences

Recent papers from ADx NeuroSciences

1. Detecting amyloid–β pathology in subjective cognitive decline using plasma and CSF biomarkersEBioMedicine · 2026
2. An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degenerationNature Medicine · 2026
3. Phosphorylated α-synuclein in CSF and plasma does not reflect synucleinopathynpj Parkinson s Disease · 2025
4. Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s diseaseAlzheimer s Research & Therapy · 2025
5. The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho‐tau Round Robin studyAlzheimer s & Dementia · 2025
6. Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217Alzheimer s Research & Therapy · 2024
7. Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217Alzheimer s Research & Therapy · 2024
8. The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study2024
9. Cerebrospinal fluid p‐tau181, 217, and 231 in definite Creutzfeldt–Jakob disease with and without concomitant pathologiesAlzheimer s & Dementia · 2024
10. Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer’s disease and a history of traumatic brain injuryNeurobiology of Aging · 2024
11. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid AngiopathyAlzheimer s Research & Therapy · 2024
12. Profiling amyloid‐β peptides as biomarkers for cerebral amyloid angiopathyJournal of Neurochemistry · 2024
13. The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer’s diseaseAlzheimer s Research & Therapy · 2024
14. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease PathologyJAMA Neurology · 2024
15. Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profilesNature Aging · 2024
16. Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PETBrain Communications · 2024
17. Preliminary performance of the Lumipulse G pTau 217 Plasma prototype assay on plasma samplesAlzheimer s & Dementia · 2023
18. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuumAlzheimer s Research & Therapy · 2023
19. Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative DementiasMolecular & Cellular Proteomics · 2023
20. Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology2023